You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-PARP-Thioparib
Thioparib

Chemical Structure : Thioparib

CAS No.: 2098639-49-5 (racemate)

Thioparib

Catalog No.: PC-49687Not For Human Use, Lab Use Only.

Thioparib is a next-generation potent, orally bioavailable pan-PARP inhibitor with IC50 of 0.13/0.006 nM (PARP1/2), overcomes multiple PARPi resistance both in vitro and in vivo.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

    Biological Activity

    Thioparib is a next-generation potent, orally bioavailable pan-PARP inhibitor with IC50 of 0.13/0.006 nM (PARP1/2), overcomes multiple PARPi resistance both in vitro and in vivo.
    Thioparib has high affinity against multiple PARPs, with an IC50 of 4.7-312 nM for PARP3, TNKS1, TNKS2, PARP6, PARP7, PARP8, PARP11, and PARP12.
    Thioparib displays high antitumor activities against PARPi-sensitive and -resistant cells with homologous recombination (HR) deficiency both in vitro and in vivo.
    Thioparib is more potent than the clinically approved PARPi Talazoparib and Olaparib.
    Thioparib inhibits PARP1-DNA dissociation using DSB FA assays with IC50 of 25.05 nM, 2- and 10-fold greater than talazoparib and olaparib, respectively.
    Thioparib shows no significant activity on sirtuins SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, and CD38 at 10 uM.
    Thioparib effectively kills HR-deficient tumors in a panel of tumor cell lines harboring BRCA1−/−, BRCA2−/−, PTEN−/−, or EWS-FLI1 gene fusion with average IC50 value of 0.96 nM.
    Thioparib (10 mg/kg, oral) exhibited antitumor effect MDA-MB-436 (BRCA1-deficient) xenografts, Thioparib (25 mg/kg, oral) significantly inhibited the growth of Capan-1 xenografts (BRCA2 deficient) in mice.
    Thioparib treatment led to PARP1-dependent DNA damage and induced S-phase arrest and apoptosis in JeKo-1 and THP-1 cells.
    Thioparib repressed homologous recombination (HR) repair activity but induced excessive RAD51 foci.
    Thioparib induced a type I IFN response through PARP7-STING/TBK1 and p38 MAPK pathways.

    Physicochemical Properties

    M.Wt 501.54
    Formula C25H20FN7O2S
    Appearance Solid
    CAS No.
    Storage
    Solide Powder
    -20°C 12 Months; 4°C 6 Months
    In Solvent
    -80°C 6 Months; -20°C 6 Months
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    (R)-4-(4-fluoro-3-(5-methyl-3-(thiazol-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)benzyl)phthalazin-1(2H)-one

    References

    1. Wang LM, et al. EMBO Mol Med. 2023 Jan 18:e16235.

    2. Chinese Patent CN201510818057.7. The United States Patent US10597399B2.

    Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    Contact Us sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    Get Quote

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • Additional Information: